| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0624908c7150e45bdd907be4f162057e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efe872551e741f0613b196b1507e5ec5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e35d2e04302e50c42ee083c76f88963
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e9fde862efc6796e2bcbb96b28f0ebb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e0e3ae73e020ecdcbd032c95da180e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29c12113afe7969c99e6602c748f1f4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccb7e0605fedc6704db670b2de77ca37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72733beec9eb20e32677c08bde3a41aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ffbd020d6474c61fb87cf629fe98749
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d8fde28f9eacdf5b3dc8fab74de9742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fa1b404b64b9f2bc4ed9a30ba7f5855 |
| publicationDate |
2020-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200021880-A |
| titleOfInvention |
A Pharmaceutical Composition For Preventing Or Treating Neuromuscular Diseases |
| abstract |
The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of neuromuscular diseases comprising extracts of the plants of the genus brucea or the indicator component of the plants of the genus Brucelia , Adam extract is transcription from SMN2 gene By improving exon 7 deficiency upon splicing of the pre-mRNA, it can be effectively used for the prevention or treatment of neuromuscular diseases such as spinal muscular atrophy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020273308-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344594-B2 |
| priorityDate |
2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |